| Date | Title | Description |
| 13.07.2023 | Diagnostic Testing Landscape Paves the Way for Consumer Centric Approach to Disease Detection | The diagnostics sector has benefited from a few trends in the past five years that not only have the potential to transform how we screen for cancer but also detect chronic conditions— such as cardiovascular disease— earlier, which could le... |
| 01.02.2023 | Sense announces agreement to be acquired by Sherlock Biosciences | Sense announces agreement to be acquired by Sherlock Biosciences
Companies enhance leadership in molecular diagnostics by pairing Sherlock’s advanced CRISPR, synthetic biology and AI technologies with Sense’s instrument-free diagnostic hard... |
| 05.10.2022 | Sense and Abacus dx agree to distribute rapid, instrument-free molecular COVID-19 test in Australia and New Zealand | Sense and Abacus dx agree to distribute rapid, instrument-free molecular COVID-19 test in Australia and New Zealand
Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement ... |
| 01.09.2022 | Sense and TECOmedical Sign Distribution Agreement for Germany, Austria, Switzerland | Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instru... |
| 09.03.2022 | Sense Biodetection sets sights on Europe after CE mark approval | Sense Biodetection sets sights on Europe after CE mark approval
BioWorld article | By Catherine Longworth
Sense Biodetection (Sense), is preparing to launch a new rapid, disposable, point-of-care molecular diagnostic test for COVID-19 in Eu... |
| 08.03.2022 | Sense Receives CE Marking for Veros™ COVID-19 Rapid, Instrument-Free Molecular Test | Sense Receives CE Marking for Veros™ COVID-19 Rapid, Instrument-Free Molecular Test
Provides Lab-Quality Accuracy (97.9%), Near Patient, in 15 Minutes
European Launch Anticipated during Q1’22
Global molecular diagnostics innovator, Sense Bi... |
| 14.12.2021 | Sense announces expansion to support lunch of rapid, Point-of-Care molecular diagnostic | Sense announces expansion of manufacturing and facilities to support lunch of rapid, Point-of-Care molecular diagnostic
Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced a large-scale investment in the expa... |
| 18.11.2021 | Sense Biodetection Secures Additional $15M in Series B Financing | Sense Biodetection, an Oxford, UK-based up-and-coming diagnostics company focused on the COVID testing landscape, secured an additional $15m in its Series B financing.
The round, which brought the total amount raised to $65m, was led by exi... |
| 17.11.2021 | The good times keep rolling for small, e-commerce business owners | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
If you’re a smaller, e-commerce shop owner looking to sell your business, now looks to be a prett... |
| 17.11.2021 | The good times keep rolling for small, e-commerce business owners | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
If you’re a smaller, e-commerce shop owner looking to sell your business, now looks to be a prett... |
| 17.11.2021 | COVID test maker Sense Biodetection pads venture round with another $15M | These days, there’s seemingly no limit to the amount of venture capital being poured into the diagnostic sector, as startups in the space continue to improve upon their already ground-breaking COVID-19 testing technologies.
Sponsored by Som... |
| 17.11.2021 | Sense announces increase of Series B to $65M to support launch of rapid, point-of-care molecular diagnostic | Sense announces increase of Series B to $65 Million to support launch of rapid, point-of-care molecular diagnostic
Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced that after achieving several key mileston... |
| 21.10.2021 | Mercia Asset Management : Health Tech is in a healthy place – Peter Dines, COO | The pandemic has had unintended consequences, acting like a wrecking ball that has helped reimagine Diagnostics and Healthcare delivery services, accelerate research and development and, critically, regulatory approvals. Solutions had to be... |
| 21.10.2021 | Health Tech is in a healthy place – Peter Dines, COO | The pandemic has had unintended consequences, acting like a wrecking ball that has helped reimagine Diagnostics and Healthcare delivery services, accelerate research and development and, critically, regulatory approvals. Solutions had to be... |
| 14.09.2021 | Sense doubles footprint with new research and development facility | Sense doubles footprint with new research and development facility
With expected approval and first product launch near, research team moves into new facility
Global molecular diagnostics innovator, Sense Biodetection (Sense) today announce... |
| 20.07.2021 | Sense appoints Timothy I. Still as President, CEO and Board Member | Sense appoints Timothy I. Still as President, CEO and Board Member Appointment of industry veteran to accelerate commercialization of company’s instrument-free molecular testing platform
Sense Biodetection, innovator of instrument-free, rap... |
| 27.04.2021 | Sense expands leadership team &, prepares for launch of the VerosTM COVID-19 instrument-free molecular test | Sense Biodetection (Sense), a leading innovator in the emerging field of instrument-free molecular diagnostics, has announced the appointment of Simon Turner as Chief Financial Officer and Ryan Roberts as Chief Commercial Officer. The Compa... |
| 23.04.2021 | Sense raises $50m Series B to accelerate launch of COVID-19 molecular test | Sense raises $50m Series B to accelerate launch of COVID-19 molecular test
23-04-2021
Sense Biodetection (Sense), has announced that it has raised a $50m Series B investment to advance commercialisation of its Veros™ COVID-19 product and co... |
| 23.04.2021 | Sense raises $50m Series B to accelerate launch of COVID-19 molecular test | Sense Biodetection (Sense), has announced that it has raised a $50m Series B investment to advance commercialisation of its Veros™ COVID-19 product and continue development of a portfolio of instrument-free, rapid molecular tests that enabl... |
| 20.04.2021 | Britons behind world's most accurate rapid Covid test raise $50m | Britons behind world's most accurate rapid Covid test raise $50m
Sense Biodetection said it expected Covid-19 to be around for the 'long-term' and could be managed using its tests
By Hannah Boland | The Telegraph
A British start-up behind w... |
| 20.04.2021 | Sense raises $50m Series B to accelerate launch of COVID-19 molecular test | Sense Raises $50m Series B to Accelerate Launch of COVID-19 molecular test on its Veros™ Instrument-Free Product Platform
The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient... |
| 18.02.2021 | Sense expands leadership team and prepares for launch of Veros™ COVID-19 instrument-free molecular test | Sense expands leadership team and prepares for launch of Veros™ COVID-19 instrument-free molecular test
Senior executives appointed to lead commercialisation of Sense's products to deliver patient focused decentralised healthcare
Sense Biod... |
| 27.01.2021 | A year in review: Business update January 2021 | Cambridge has always been at the forefront of innovation. As the leading venture capital investor in Cambridge, CIC plays a central role in commercialising this innovation for the benefit of society. In the last year, CIC’s existing portfol... |
| 22.06.2020 | Annual results for the year ended 31 March 2020 | Expansion to 30 portfolio companies and 46% increase in net asset value, reinforcing CIC’s position as the most active series A investor in the Cambridge ecosystem
Cambridge Innovation Capital plc (CIC), the venture capital investor enablin... |
| 16.05.2020 | Sense reported on CBS Weekend News | Sense Biodetection's Veros SARS-CoV-2 test kit, a simple disposable test for coronavirus, reported on CBS Weekend News
Medical companies rush to develop accurate coronavirus test kits
Watch the news clip here
For further details about Sense... |
| 13.05.2020 | Sense: Koch partner to develop rapid COVID-19 test | Sense of urgency: Koch partnering to develop rapid COVID-19 test
Article by Koch Newsroom
Phillips-Medisize is helping Sense Biodetection produce a first-of-its-kind molecular diagnostic test that can be administered anywhere and provides a... |
| 13.04.2020 | Instrument-Free POC Molecular Coronavirus Test Being Developed by Sense | Article by Leo O'Connor, GenomeWeb
NEW YORK – Sense Biodetection is accelerating the development of an instrument-free molecular platform for SARS-CoV-2, the coronavirus that causes COVID-19, in a bid to provide more sensitive point-of-care... |
| 06.04.2020 | SPOTLIGHT ON: COVID-19 Testing - Insights into some whats and whys | Article by FirstWord MedTech including an interview with Harry Lamble, CEO of Sense Biodetection
The ever-expanding and increasingly diverse COVID-19 testing landscape can be confusing to navigate and comprehend. In this article, FirstWord ... |
| 31.10.2019 | Mercia-backed diagnostics company raises £12.3m | Sense Biodetection, the Cambridge-based diagnostics company which is backed by Mercia, has raised £12.3m to develop a new range of tests, initially targeting infectious diseases like flu. |
| 29.10.2019 | Cambridge-based Sense Biodetection raises €14 million to develop its point-of-care diagnostic tests | Cambridge-based Sense Biodetection (or Sense) has raised €14 million to develop its portfolio of instrument-free, point-of-care molecular diagnostic tests, a pioneering new class of diagnostic product.
The company raised €10 million in Seri... |
| 29.10.2019 | Sense Biodetection Raises £12.3m in Funding | Sense Biodetection Limited, a Cambridge, UK-based molecular diagnostics company, raised £12.3m in funding.
The round included:
– £10.5m Series A investment co-led by Cambridge Innovation Capital (CIC) and Earlybird, with participation from ... |
| 29.10.2019 | CIC co-leads Sense Biodetection’s £12.3 million Series A financing | Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, has co-led the £12.3 million Series A funding round raised by Sense Biodetection (... |
| 29.10.2019 | Sense Biodetection raises £12.3m to progress instrument-free molecular diagnostics | Sense Biodetection raises £12.3m to progress instrument-free molecular diagnostics
29-10-2019
Sense Biodetection Limited (Sense) developers of simple, ultra-rapid, handheld tests for flu and other infectious diseases has raised £12.3M, in a... |
| 29.10.2019 | Sense Biodetection raises £12.3m to progress instrument-free molecular diagnostics | Sense Biodetection Limited (Sense) developers of simple, ultra-rapid, handheld tests for flu and other infectious diseases has raised £12.3M, in a funding round led by Cambridge Innovation Capital, with participation from Jonathan Milner.
S... |
| 03.08.2018 | Heiner Dreismann Joins Sense as Chairman | Mercia EIS Funds’ portfolio company, Sense Biodetection Limited (Sense) has announced the appointment of Heiner Dreismann as non-executive Chairman. Heiner was previously the President and CEO of Roche Molecular Systems, the world leader in... |
